Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says

Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet